Enlivex Therapeutics Ltd.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Enlivex develops immunotherapy solutions for inflammatory diseases and critical conditions.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 173.8 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 36.3 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 149.8 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 36.3 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 271.6 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 36.5 KB | |
| 2025-05-14 01:32 |
Prospectus
Renewal of ATM plan
|
English | 545.8 KB | |
| 2025-05-14 01:32 |
Foreign Filer Report
Renewal of ATM plan
|
English | 36.3 KB | |
| 2025-05-03 02:24 |
Registration Form
FORM F-3-prospectus in one or more offerings
|
English | 617.9 KB | |
| 2025-05-03 02:24 |
Foreign Filer Report
FORM F-3-prospectus in one or more offerings
|
English | 36.3 KB | |
| 2025-05-01 02:02 |
Foreign Filer Report
20F For the fiscal year ended December 31, 2024
|
English | 1.7 MB | |
| 2025-05-01 02:02 |
Foreign Filer Report
20F For the fiscal year ended December 31, 2024
|
English | 36.5 KB | |
| 2025-04-23 17:45 |
Foreign Filer Report
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
|
English | 175.9 KB | |
| 2025-04-23 17:45 |
Foreign Filer Report
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
|
English | 36.2 KB | |
| 2025-04-21 18:05 |
Foreign Filer Report
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluati…
|
English | 150.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
MedinCell S.A. | France | MEDCL | |
|
Mendus | Sweden | IMMU | |
|
Merchavia Holdings and Investments Ltd. | Israel | MRHL | |
|
Merck KGaA | United States of America | 6MK | |
| Metabolic Nordic AB | Sweden | MBOLIC | ||
|
Modus Therapeutics Holding AB | Sweden | MODTX | |
|
Molecure S.A. | Poland | MOC | |
|
M WINKWORTH PLC | United Kingdom | WINK | |
|
Mycodern Spolka Akcyjna | Poland | MCD | |
|
Nanexa AB | Sweden | NANEXA |